Vir hepatitis D drug succeeds in first pivotal study

Vir Biotechnology reported positive results from a Phase 3 trial of its hepatitis D drug combination, elebsiran and tobevibart, meeting primary and secondary endpoints. The treatment achieved a 44% response rate in 48 weeks, with 79% of patients showing reduced viral levels. Vir plans to submit regulatory data in 2027 if further trials succeed. Hepatitis D affects 5% of chronic hepatitis B cases globally, with limited current treatments. Analysts predict the drug could become a leading therapy.

Original reporting

finance.yahoo.com

Published Nov 9, 2026, 5:09 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 9, 2026, 5:25 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Vir hepatitis D drug succeeds in first pivotal study — source image — Source · finance.yahoo.com

Decision brief

The 30-second read

$VIRBullishMed

Why it matters

The trial success may catalyze a re‑rating of Vir's valuation and spark interest in similar viral‑hepatitis assets.

Market read

First pivotal data for a niche hepatitis D therapy, driving a 12% stock move and potential sector re‑rating.

What to watch

Regulatory timeline uncertainty and the need for two additional Phase 3 trials could delay commercialization.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Vir Biotechnology, a NASDAQ‑listed biotech, recently pivoted to oncology but retained infectious‑disease programs, including hepatitis D.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$VIRBullishHigh confidence

Context

Vir's two-drug combination succeeded in the first pivotal Phase 3 trial for chronic hepatitis D, sending the stock up about 12% in early Monday trading.

Expected impact

likely upward pressure as investors price in potential regulatory approval and market share gains

Evidence & confidence

First‑report pivotal data with clear efficacy signals; analyst note calls it a preferred future product.

Market effects

Sector

strengthens the biotech sector's pipeline narrative for infectious‑disease therapies

Regional

U.S. biotech investors may see increased demand for hepatitis D assets

Global

could influence global hepatitis D treatment landscape and competitor pipelines

Counterpoint

What could challenge this read

If cross‑trial caveats prove material, the market may overprice the upside and a correction could follow.

Key entities

company
Vir Biotechnology
Developer of the elebsiran/tobevibart regimen for hepatitis D.
analyst_firm
Evercore ISI
Provided a client note highlighting the data's potential market impact.

Read at source ← All news

$VIRMedAI 9/10

Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48

Vir Biotechnology's hepatitis delta treatment met Phase III goals, with 79% of patients virus-free at week 48. The trial showed 85% efficacy in patients with cirrhosis. No serious adverse events were reported. Vir plans to submit data to the FDA in mid-2027. The company expects top-line results from ECLIPSE 2 and 3 trials in Q1 2027.

finance.yahoo.comNov 10

$VIRHighAI 9/10

Vir Biotechnology’s hepatitis D drug scores in Phase II and Phase III trials

Vir Biotechnology's combination of elebsiran and tobevibart met primary endpoints in Phase II and III trials for chronic hepatitis delta, with 44% of patients achieving undetectable virus and ALT normalization at week 48. The treatment was well-tolerated. According to the company, the results position the therapy as a potential best-in-disease treatment.

clinicaltrialsarena.comNov 10

$VIRHighAI 9/10

Elebsiran and Tobevibart Meet Primary End Point in Hepatitis Delta Study

Vir Biotechnology's combination of elebsiran and tobevibart met the primary endpoint in the ECLIPSE 1 trial, with 44% of patients achieving undetectable HDV RNA and ALT normalization at week 48, compared to 0% in the delayed-treatment arm. The company plans to submit a global regulatory package, and Norgine holds exclusive rights for Europe, Australia, and New Zealand.

contagionlive.comNov 9

$EDSAMedAI 8/10

Healthcare Stocks Rally: EDSA And DCTH Jump 30%, VIR And IMVT Also Gain

Edesa Biotech (EDSA) and Delcath Systems (DCTH) shares rose 30% after signing a licensing deal and reporting strong Q3 results, respectively. Immunovant (IMVT) and Vir Biotechnology (VIR) shares gained 13% and 14% following positive clinical trial data. EDSA received $12M upfront, DCTH raised FY26 revenue outlook, IMVT met primary endpoint, and VIR showed undetectable HDV RNA in 28 patients.

rttnews.comNov 9

$VIRMedAI 8/10

Gilead Rival Shoots To Two-Year High On Hepatitis D News

Vir Biotechnology (VIR) shares reached a near two-year high after its hepatitis D treatment, tobevibart and elebsiran, showed positive results in a 48-week study. All patients exhibited a virological response, with 79% showing undetectable virus levels, according to the company.

investors.comNov 9

$VIRHighAI 8/10

Vir Biotechnology Stock Jumps 14%

Vir Biotechnology (VIR) shares rose 13.92% to $13.91 after reporting Phase 2 trial data showing 100% of patients achieved undetectable hepatitis delta virus levels. 89% of patients showed improved or stable liver stiffness. The stock's 52-week range is $5.22 to $14.38, with volume at 4.08 million shares. The company plans a Phase 3 ECLIPSE program with a 2027 regulatory filing.